News
ACRV
8.77
+7.74%
0.63
Weekly Report: what happened at ACRV last week (0429-0503)?
Weekly Report · 5d ago
Acrivon Therapeutics Cut to Neutral From Buy by Ladenburg Thalmann
Dow Jones · 04/29 13:22
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral
Benzinga · 04/29 13:12
Weekly Report: what happened at ACRV last week (0422-0426)?
Weekly Report · 04/29 09:40
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Two analysts have maintained Buy ratings on VistaGen Therapeutics and Acrivon Therapeutic, Inc. Maxim Group and H.C. Wainwright both have bullish sentiments on the Healthcare sector. The company’s shares closed last Friday at $4.75.
TipRanks · 04/27 12:10
Acrivon Therapeutics Price Target Raised to $25.00/Share From $18.00 by BMO Capital
Dow Jones · 04/26 18:12
Acrivon Therapeutics Is Maintained at Outperform by BMO Capital
Dow Jones · 04/26 18:12
BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25
Benzinga · 04/26 18:01
Buy Rating on Acrivon Therapeutics with Increased Target Price Amid Promising ACR-368 Trial Data
TipRanks · 04/26 11:20
ACRIVON THERAPEUTICS INC <ACRV.O>: BMO RAISES TARGET PRICE TO $25 FROM $18
Reuters · 04/26 11:01
Acrivon Therapeutics Price Target Raised to $17.00/Share From $14.00 by JMP Securities
Dow Jones · 04/25 16:53
Acrivon Therapeutics Is Maintained at Market Outperform by JMP Securities
Dow Jones · 04/25 16:53
Acrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market Potential
TipRanks · 04/25 16:46
JMP Securities Maintains Market Outperform on Acrivon Therapeutics, Raises Price Target to $17
Benzinga · 04/25 16:43
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Healthcare On the Move: Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers. S&P 500 Health Care Sector -0.23% to 1637.36. Pharmaceuticals and Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/25 14:00
Acrivon Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 04/25 13:04
Acrivon Therapeutics Price Target Raised to $30.00/Share From $26.00 by Piper Sandler
Dow Jones · 04/25 13:04
Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $30
Benzinga · 04/25 12:53
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Acrivon Therapeutics, Inc. (ACRV) and Viking Therapeutics (VKTX)
TipRanks · 04/25 12:07
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Intelligent Living (NASDAQ:ILAG) stock is rocketing more than 78% alongside heavy pre-market trading this morning. Moving stocks this morning are earnings reports, clinical trial data, a delisting notice and more. Biggest Pre-Market Stock Movers: 10 Top Gainers and 10 Top Losers.
Investorplace · 04/25 11:33
More
Webull provides a variety of real-time ACRV stock news. You can receive the latest news about Acrivon Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.